Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CAPS's Cash to Debt is ranked higher than
93% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. CAPS: No Debt )
CAPS' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CAPS's Interest Coverage is ranked higher than
82% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CAPS: No Debt )
CAPS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -33.06
M-Score: -4.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -54.33
CAPS's ROE (%) is ranked higher than
61% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. CAPS: -54.33 )
CAPS' s 10-Year ROE (%) Range
Min: -137.33   Max: 58.43
Current: -54.33

-137.33
58.43
ROA (%) -53.59
CAPS's ROA (%) is ranked higher than
59% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. CAPS: -53.59 )
CAPS' s 10-Year ROA (%) Range
Min: -66.08   Max: 55.67
Current: -53.59

-66.08
55.67
ROC (Joel Greenblatt) (%) -3156.62
CAPS's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. CAPS: -3156.62 )
CAPS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9605.65   Max: -0.21
Current: -3156.62

-9605.65
-0.21
EBITDA Growth (%) -29.10
CAPS's EBITDA Growth (%) is ranked higher than
60% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CAPS: -29.10 )
CAPS' s 10-Year EBITDA Growth (%) Range
Min: -36.8   Max: 87.4
Current: -29.1

-36.8
87.4
EPS Growth (%) -28.20
CAPS's EPS Growth (%) is ranked higher than
64% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. CAPS: -28.20 )
CAPS' s 10-Year EPS Growth (%) Range
Min: -41.8   Max: 108
Current: -28.2

-41.8
108
» CAPS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CAPS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.58
CAPS's P/B is ranked higher than
84% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. CAPS: 2.58 )
CAPS' s 10-Year P/B Range
Min: 0.08   Max: 5.77
Current: 2.58

0.08
5.77
EV-to-EBIT -1.56
CAPS's EV-to-EBIT is ranked higher than
72% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CAPS: -1.56 )
CAPS' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 124
Current: -1.56

0.1
124
Current Ratio 10.55
CAPS's Current Ratio is ranked higher than
89% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. CAPS: 10.55 )
CAPS' s 10-Year Current Ratio Range
Min: 2.57   Max: 140.04
Current: 10.55

2.57
140.04
Quick Ratio 10.55
CAPS's Quick Ratio is ranked higher than
90% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. CAPS: 10.55 )
CAPS' s 10-Year Quick Ratio Range
Min: 1.8   Max: 140.04
Current: 10.55

1.8
140.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.45
CAPS's Price/Net Cash is ranked higher than
96% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. CAPS: 3.45 )
CAPS' s 10-Year Price/Net Cash Range
Min: 0.39   Max: 181.26
Current: 3.45

0.39
181.26
Price/Net Current Asset Value 3.45
CAPS's Price/Net Current Asset Value is ranked higher than
95% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. CAPS: 3.45 )
CAPS' s 10-Year Price/Net Current Asset Value Range
Min: 0.39   Max: 43.76
Current: 3.45

0.39
43.76
Price/Tangible Book 3.10
CAPS's Price/Tangible Book is ranked higher than
89% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. CAPS: 3.10 )
CAPS' s 10-Year Price/Tangible Book Range
Min: 0.36   Max: 10.47
Current: 3.1

0.36
10.47
Forward Rate of Return (Yacktman) -93.72
CAPS's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. CAPS: -93.72 )
CAPS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.7   Max: 48
Current: -93.72

0.7
48

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Capstone Therapeutics Corp was incorporated as a Delaware corporation in July 1987 as IatroMed, Inc. On May 21, 2010 the name was changed to Capstone Therapeutics Corp. It is a biotechnology company which develops a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. On August 3, 2012, it entered into a joint venture, LipimetiX Development, LLC, to develop Apo E mimetic peptide molecule AEM-28 and its analogs. Its development activities represent a single operating segment as they shared the same product development path and utilized the same company resources. The biotechnology companies and public institutions compete with the Company in recruiting for research personnel and subjects, which affect its ability to complete research studies.
» More Articles for CAPS

Headlines

Articles On GuruFocus.com
Orthologic Corp. Reports Operating Results (10-Q) Nov 10 2010 
Orthologic Corp. Reports Operating Results (10-Q) Aug 09 2010 
Orthologic Corp. Reports Operating Results (10-Q) Nov 09 2009 
Orthologic Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
CAPSTONE THERAPEUTICS CORP. Financials Aug 23 2014
Capstone Therapeutics Will Provide an Operating Update and Announces Second Quarter 2014 Financial... Aug 14 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 14 2014
Capstone Therapeutics Will Provide an Operating Update and Announces Second Quarter 2014 Financial... Aug 14 2014
Capstone Therapeutics Announces Second Quarter 2014 Financial Results and Operating Update... Aug 06 2014
Capstone Therapeutics Announces Second Quarter 2014 Financial Results and Operating Update... Aug 06 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Jun 24 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jun 17 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 11 2014
Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in... Jun 11 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition,... May 21 2014
Capstone Therapeutics to host conference call May 16 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-Q, Quarterly Report May 15 2014
Capstone Therapeutics Announces Operating Update Conference Call, Planned Initiation of AEM-28 Phase... Mar 27 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 27 2014
Capstone Therapeutics Announces Operating Update Conference Call Mar 24 2014
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 21 2013
Capstone Therapeutics Announces a LipimetiX Development, LLC Presentation at the American Heart... Nov 19 2013
Capstone Therapeutics to Hold Quarterly Operating Update Conference Call Nov 12 2013
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-Q, Quarterly Report Nov 12 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK